AMBOSS and OpenEvidence are two of the most prominent clinical AI platforms in the world. Both are growing fast in 2026. Both are expanding beyond their original category. But the direction of their expansion reveals fundamentally different strategic visions — and understanding the divergence helps clinicians choose the right tool for the right job.
AMBOSS: Expanding Toward Intelligence and Learning
AMBOSS began as a medical knowledge library with an integrated Q-Bank. Its 2026 expansion is toward depth and career-stage continuity.
AI Mode Learning uses adaptive, AI-driven personalisation to create study sessions that target individual knowledge gaps. The AMBOSS Library continues to deepen its clinical content with expert-authored learning cards. The Anki integration bridges AMBOSS content into the spaced-repetition ecosystem that millions of medical students already use. And the platform increasingly targets not just students but practising clinicians who need ongoing knowledge maintenance.
The thesis: AMBOSS wants to be the medical intelligence platform that clinicians use from medical school through their entire career — deepening their knowledge at every stage.
OpenEvidence: Expanding Toward Workflow and Revenue
OpenEvidence began as a clinical evidence search engine for verified healthcare professionals. Its 2026 expansion is toward breadth and workflow capture.
The Sutter Health/Epic embedding puts evidence retrieval inside the EHR. Doctor Dialer adds patient communications with AI documentation. Coding Intelligence adds revenue capture. Visits provides the documentation layer. The $250 million Series D at a $12 billion valuation funds further expansion.
The thesis: OpenEvidence wants to be the workflow layer through which clinicians access evidence, communicate with patients, document encounters, and capture revenue — all in a single platform.
Two Logics, One Market
AMBOSS is going deeper. OpenEvidence is going wider. AMBOSS is investing in knowledge quality and learning science. OpenEvidence is investing in workflow integration and revenue tools.
For clinicians, the practical implication is that these platforms are becoming less competitive and more complementary over time. AMBOSS is the tool you use to learn and maintain clinical knowledge. OpenEvidence is the tool you use to act on that knowledge during the clinical day — searching evidence, documenting visits, communicating with patients, and coding encounters.
Where iatroX Fits
iatroX spans both logics. It provides guideline-grounded clinical reference (evidence retrieval, like OpenEvidence) and structured learning with adaptive Q-Banks and spaced repetition (knowledge building, like AMBOSS). For UK clinicians specifically, it adds the NICE/CKS/SIGN/BNF grounding that neither AMBOSS nor OpenEvidence prioritises.
The Ask feature serves the evidence retrieval function. The Q-Bank and Brainstorm serve the learning function. The CPD module bridges both — turning clinical queries into documented professional development. And it is free, with no institutional login required.
For UK clinicians navigating the global AI landscape, iatroX provides the UK-specific layer that both AMBOSS and OpenEvidence are expanding away from as they pursue broader global and workflow ambitions.
Conclusion
AMBOSS and OpenEvidence are both excellent platforms executing different strategies. AMBOSS is building the deepest medical intelligence platform. OpenEvidence is building the broadest clinical workflow platform. Understanding the difference helps clinicians choose the right tool — or, more likely, the right combination.
For UK clinicians who need guideline-grounded reference, structured learning, and professional development in a single free platform, iatroX remains the most directly useful option.